Key facts
- It has raised $19.1M; the latest was Later Stage VC ($1.5M) in Dec 2024.
- Notable investors include Innovate UK, Mercia Ventures, European Regional Development Fund (Brandenburg), Northstar Ventures, NVM Private Equity — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Newcells Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Newcells Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Newcells Biotech
Developer of a biotechnology platform designed to develop in vitro cell-based assays for early drug discovery and development. The company's platform is focused on building models that closely mimic the physiology of the kidney, retina, liver, and lung that improve prediction of safety, pharmacology, and efficacy in humans and commercialized kidney and retina platforms as best in class and development for launch stem cell-based models of the liver and lung, enabling researchers to research and test new drugs and screen potential drug molecules for efficacy and toxicity.
- Sector
- Healthcare
- HQ
- Newcastle Upon Tyne, United Kingdom
- Founded
- 2015
- Employees
- 47
- Website
- newcellsbiotech.co.uk/
- Ownership
- Privately Held (backing)
Newcells Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Newcells Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Newcells Biotech in its N-PORT filings yet. We sweep new filings monthly.